![](/img/cover-not-exists.png)
PCN248 ESTIMATING THE UNBIASED OS-BENEFIT FOR APALUTAMIDE (APA) VERSUS ANDROGEN DEPRIVATION THERAPY (ADT) IN PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) FROM SPARTAN, ADJUSTING FOR SUBSEQUENT THERAPY USING RANDOMIZED DATA EXTERNAL TO THE TRIAL
Diels, J., Perualila, N., Sermon, J., Siebert, U., van Sanden, S.Volume:
22
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.04.369
Date:
May, 2019
File:
PDF, 322 KB
english, 2019